Synthesis and pharmacological properties of 5H,10H-imidazo[1,2- a]indeno[1,2-e]pyrazine,4-one, a new competitive AMPA/KA receptor antagonist

Drug Development Research

Volumn 48, Issue 3, 1999, Pages 121-129

  Mignani, Serge ^a   Aloup, Jean Claude ^a   Barreau, Michel ^a   Blanchard, Jean Charles ^a   Böhme, Georg Andrees ^a   Boireau, Alain ^a   Damour, Dominique ^a   Debono, Marc Williams ^a   Dubroeucq, Marie Christine ^a   Genevois Borella, Arielle ^a   Imperato, Assunta ^a   Jimonet, Patrick ^a   Pratt, Jeremy ^a   Randle, John C R ^a   Reibaud, Michel ^a   Ribeill, Yves ^a   Stutzmann, Jean Marie ^a  

^a SANOFI   (France)

Author keywords

AMPA KA antagonists; Anticonvulsant agent; Neuroprotective agent

Indexed keywords

5,7 DICHLOROKYNURENIC ACID; 5H,10H IMIDAZO[1,2 A]INDENO[1,2 E]PYRAZIN 4 ONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; KAINIC ACID RECEPTOR ANTAGONIST; NEUROPROTECTIVE AGENT; POTASSIUM CHLORIDE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICONVULSANT THERAPY; ARTICLE; BRAIN PROTECTION; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GERBIL; INTOXICATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROTRANSMISSION; NONHUMAN; RAT; SEIZURE; SPINAL CORD INJURY;

EID: 0033388441     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199911)48:3<121::AID-DDR4>3.0.CO;2-E     Document Type: Article

References (33)

1. Aloup JC, Audiau F, Damour D, Genevois-Borella A, Jimonet P, Mignani S. 1993. Derivatives of 5H, 10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, preparation there of and medicaments containing them. Patent Applications WO 94/9407893. Chem Abstr 1994 121:1111.
2. Auberson YP, Bischoff S, Moretti R, Schmutz M, Veenstra SJ. 1998. 5-Aminomethylqumoxaline-2,3-diones. I. A novel class of AMPA receptor antagonists. Bioorg Med Chem Lett 8:65-70.
3. Benzel CE, Lancon JA, Thomas MM, Beal JA, Hoffpauir GM, Kesterson LA. 1990. New rat spinal cord injury model: a ventral compression technique. J Spinal Disord 3:334-338.
4. Bigge CF, Nikam SS. 1997. AMPA receptor agonist, antagonists and modulators: their potential for clinical utility. Exp Opin Ther Patents 7:1099-1114.
5. Buchan AM, Li H, Cho S, Pulsinelli WA. 1991. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci Lett 132:255-258.
6. 3H]-dichlorokynurenic acid. J Pharm Pharmacol 44:812-816.
7. Chapman A. 1991. Excitatory amino acid antagonists and therapy of epilepsy. In: Meldrum BS, editor. Excitatory amino acid antagonists. Oxford: Blackwell Scientific Publications. p 265-286.
8. Chapman AG, Meldrum BS, Nanji N, Watkins JC. 1987. Anticonvulsant action and biochemical effects in DBA/2 mice of CPP (3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate, a novel N-methyl-D-aspartate. Eur J Pharmacol 139:91-96.
9. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
10. Collingridge GL, Singer W. 1990. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 11:290-291.
11. Croucher MJ, Collins JF, Meldrum BS. 1982. Anticonvulsant action of excitatory amino acid antagonists. Science 216:899-901.
12. Damour D, Aloup JC, Barreau M, Genevois-Borella A, Jimonet P, Leconte P, Ribeill Y, Vuilhorgne M, Mignani S. 1999. An efficient preparative route to fused imidazo[1,2-a]pyrazin-4-one derivatives. Heterocycles 50:259-265.
13. Davey DD. 1987. Synthesis of 6-phenylimidazo[1,2-a]pyrazin-8-one and 1-methyl-6-phenylimidazo[1,5-a]pyrazin-8-one via quaternary intermediates. J Org Chem 52:4379-4381.
14. Debono MW, Le Guern J, Canton T, Dohle A, Pradier L. 1993. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 235:283-289.
15. Epperson JR, Hewawasam P, Meanwell NA, Boissard CG, Gribkoff VK, Post-Munson D. 1993. Synthesis and excitatory amino acid pharmacology of some novel quinoxalinediones. Bioorg Med Chem Lett 3:2801-2804.
16. Galeazzi E, Guzman A, Nava JL, Liu Y, Maddox ML, Muchowski JM. 1995. Improved synthesis of imidazole-2-carboxaldehyde, imidazole-2-carboxylic acid and ethyl imidazole-2-carboxylate. J Org Chem 60:1090-1092.
17. Honoré T, Drejer J. 1988. Chaotropic ions after conformation of quisqualate receptors in rat cortical membranes. J Neurochem 51:457-461.
18. Jackson PF, Davenport TW, Resch JF, Lehr GS, Pullan LM. 1991. Tricyclic quinoxalines as ligands for the strychnine-insensitive glycine site. Biorg Med Chem Lett 1:751-756.
19. Liu D, Thangnipon W, McAdoo D. 1991. Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res 547:344-348.
20. Malgouris C, Bardot F, Daniel M, Pellis F, Rataud J, Uzan A, Blanchard JC, Laduron P. 1989. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 9(11):3720-3727.
21. McQuaid LA, Smith ECR, South KK, Mitch CH, Schoepp DD, True RA, Calligaro DO, O'Malley PJ, Lodge D, Ornstein P. 1992. Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones. J Med Chem 35:3319-3324.
22. Meldrum BS. 1991. Historical introduction: key discoveries. In: Meldrum BS, editor. Excitatory amino acid antagonists. Oxford: Blackwell Scientific Publication. p 1-13.
23. Monaghan DT, Bridges RJ, Ctmann CW. 1989. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365-402.
24. Ohmori J, Sakamoto S, Kubota H, Shimizu-Sasamata M, Okada M, Kawasaki S, Hidaka K, Togami J, Furuya T, Murase K. 1994. 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J Med Chem 37:467-475.
25. Ohmori J, Shimizu-Sasamata M, Okada M, Sakamoto S. 1997. 8-(1H-Imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-a]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. J Med Chem 40:2053-2063.
26. Olney JW. 1989. Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26(5):505-525.
27. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron P, Stutzmann JM. 1992. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci Lett 140:225-230.
28. Rivlin A, Tator, C. 1977. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosci 47:577-581.
29. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honoré T. 1990. 2,3-Dihydro-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247:571-574.
30. Snell LD, Morter RS, Johnson KM. 1988. Structural requirements for activation of the glycine receptor that modulates the N-methyl-D-aspartate operated ion channel. Eur J Pharmacol 156:105.
31. Swinyard, EA, Brown WC, Goodman LS. 1952. Comparative assays of anti-epileptic drugs in mice and rats. J Pharmacol Exp Ther 106:319-330.
32. Tamura L, Graham DI, McCulloch J, Teasdale GM. 1981. Focal cerebral ischemia in the rat: description of the technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab 1:53-60.
33. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB. 1988. NMDA receptor losses in putamen from patients with Huntington's disease. Science 241:981-983.